Implantable Neurostimulator Treats Central Sleep Apnea
By HospiMedica International staff writers Posted on 25 Aug 2021 |
Image: The remedé EL-X helps treat central sleep apnea (Photo courtesy of ZOLL Respicardia)
A next-generation implantable system delivers electrical pulses to one of the phrenic nerves, which send signals to the diaphragm, restoring a more normal breathing pattern during sleep.
The ZOLL Medical Corporation (ZOLL; Chelmsford, MA, USA) remedē EL-X system is designed to provide transvenous phrenic nerve stimulation to the left pericardiophrenic or right brachiocephalic vein in order to provide neurostimulation to the adjacent phrenic nerve, resulting in diaphragmatic contractions during sleep. A more stabilized gas exchange and improved breathing pattern is thus established, resulting in fewer apneic events, improved oxygen saturation, and increased end-tidal carbon dioxide (etCO2).
The system includes the battery-powered pulse generator, implanted subcutaneously in the upper chest and an external system programmer. The new remedē EL-X model delivers extended longevity, reduced size, and an enhanced suite of diagnostics compared to the previous model, with 40% longer battery life, a simplified single-lead, single-port system that provides both stimulation and sensing from a single lead, and new data-driven clinical insights view DRēAM View, a software suite that includes full-night, comprehensive diagnostic capabilities.
“The next-generation remedē System is built on the proven success of the current platform, with the needs of both patients and clinicians in mind,” said Pete Sommerness, President of ZOLL Respicardia. “The increased longevity, smaller size, enhanced diagnostics, and simplified implant procedure will substantially benefit patients.”
There are two primary classifications of sleep apnea, obstructive sleep apnea (OSA) and CSA. OSA results from a blockage of the upper airway; CSA occurs when the brain fails to send appropriate signals to the breathing muscles that stimulate a regular breathing pattern. CSA symptoms include chronic fatigue, excessive daytime sleepiness, cognitive impairment and inability to get restful sleep. Many patients with CSA also have heart disease, especially heart failure (HF), and are at increased risk for hospitalizations and even death.
The ZOLL Medical Corporation (ZOLL; Chelmsford, MA, USA) remedē EL-X system is designed to provide transvenous phrenic nerve stimulation to the left pericardiophrenic or right brachiocephalic vein in order to provide neurostimulation to the adjacent phrenic nerve, resulting in diaphragmatic contractions during sleep. A more stabilized gas exchange and improved breathing pattern is thus established, resulting in fewer apneic events, improved oxygen saturation, and increased end-tidal carbon dioxide (etCO2).
The system includes the battery-powered pulse generator, implanted subcutaneously in the upper chest and an external system programmer. The new remedē EL-X model delivers extended longevity, reduced size, and an enhanced suite of diagnostics compared to the previous model, with 40% longer battery life, a simplified single-lead, single-port system that provides both stimulation and sensing from a single lead, and new data-driven clinical insights view DRēAM View, a software suite that includes full-night, comprehensive diagnostic capabilities.
“The next-generation remedē System is built on the proven success of the current platform, with the needs of both patients and clinicians in mind,” said Pete Sommerness, President of ZOLL Respicardia. “The increased longevity, smaller size, enhanced diagnostics, and simplified implant procedure will substantially benefit patients.”
There are two primary classifications of sleep apnea, obstructive sleep apnea (OSA) and CSA. OSA results from a blockage of the upper airway; CSA occurs when the brain fails to send appropriate signals to the breathing muscles that stimulate a regular breathing pattern. CSA symptoms include chronic fatigue, excessive daytime sleepiness, cognitive impairment and inability to get restful sleep. Many patients with CSA also have heart disease, especially heart failure (HF), and are at increased risk for hospitalizations and even death.
Latest Critical Care News
- Stretchable Microneedles to Help In Accurate Tracking of Abnormalities and Identifying Rapid Treatment
- Machine Learning Tool Identifies Rare, Undiagnosed Immune Disorders from Patient EHRs
- On-Skin Wearable Bioelectronic Device Paves Way for Intelligent Implants
- First-Of-Its-Kind Dissolvable Stent to Improve Outcomes for Patients with Severe PAD
- AI Brain-Age Estimation Technology Uses EEG Scans to Screen for Degenerative Diseases
- Wheeze-Counting Wearable Device Monitors Patient's Breathing In Real Time
- Wearable Multiplex Biosensors Could Revolutionize COPD Management
- New Low-Energy Defibrillation Method Controls Cardiac Arrhythmias
- New Machine Learning Models Help Predict Heart Disease Risk in Women
- Deep-Learning Model Predicts Arrhythmia 30 Minutes before Onset
- Breakthrough Technology Combines Detection and Treatment of Nerve-Related Disorders in Single Procedure
- Plasma Irradiation Promotes Faster Bone Healing
- New Device Treats Acute Kidney Injury from Sepsis
- Study Confirms Safety of DCB-Only Strategy for Treating De Novo Left Main Coronary Artery Disease
- Revascularization Improves Quality of Life for Patients with Chronic Limb Threatening Ischemia
- AI-Driven Prediction Models Accurately Predict Critical Care Patient Deterioration